I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ADPD 2021

-
09:15 AM
Duration 15mins Virtual
Utilisation of home nursing to mitigate the impact of COVID-19 on the conduct of the gantenerumab graduate trials
Searle A, Thanasopoulou A, Kenton J, Voyle N, Thorne N, Baudler M, Doody R, Kerchner GA
12:15 PM
Duration 15mins Virtual
Translation of RG6102, an amyloid-targeting therapy with superior brain penetration properties, to the clinic
Kulic L, Hofmann C, Janssen N, Grimm HP, Abrantes J, Schumacher V, Marchesi M, Niewöhner J, Svoboda H
09:00 AM
Duration 15mins Virtual
A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): Results from Part 1 Week 52
Gennaro Pagano, F Boess K.I Taylor B Mollenhauer W Poewe, M Marchesi, A Boulay, J Anzures-Cabrera, A Vogt, T Nikolcheva, W Zago, R Tripuraneni, D.K Ness, H Svoboda, M Britschgi, R Doody, P Fontoura, D Umbricht, and A Bonni for the Prasinezumab Study Group
09:15 AM
Duration 15mins Virtual
Roche PD Mobile Application v2 Detects Slowing of Early Parkinson’s Disease Progression under Prasinezumab: PASADENA Phase II Part 1 Results
Kirsten I. Taylor, Florian Lipsmeier, Ekaterina Volkova-Volkmar, Daria Rukina, Judith Anzures Cabrera, Laurent Essioux, Markus Abt, Ben van Lier , Alessandra E. Thomann, Hanno Svoboda, Wagner Zago, Gennaro Pagano, Ronald B. Postuma & Michael Lindemann
09:30 AM
Duration 15mins Virtual
Clinically meaningful change of motor symptoms and decline in daily life functioning in levodopa-treated patients with Parkinson´s Disease
Loes Rutten-Jacobs, Dylan Trundell, Annabelle Monnet, Nathalie Pross, Hanno Svoboda, Tania Nikolcheva, Gennaro Pagano
01:15 PM
Duration 15mins Virtual
CSF Pharmacokinetic and pharmacodynamics of semorinemab from a Phase 2 Trial in Prodromal-to-Mild Alzheimer's Disease (Tauriel)
Wildsmith KR, Toth B, Lee J, Ramakrishnan V, Dolton M, Brooks L, Schauer SP, Carrasco-Triguero M, Manser PT, Keeley M, Teng E
11:15 AM
Duration 15mins Virtual
Benchmarking Disease Modifying Therapies for Alzheimer's Disease Using a Quantitative Systems Pharmacology Model
Ramakrishnan V, Friedrich C, Witt C, Sheehan R, Pryor M, Dolton M, Atwal J, Wildsmith K, Kudrycki K, Lee SH, Grimm HP, Aldea R, Mazer N, Hofmann C, Gieschke R, Fuji R, Ramanujan S, Quartino A, Jin JY
Coming soon